April 25, 2017
The Canadian federal government’s initiatives to legalize recreational cannabis and its efforts in relation to public policy is setting a global example that is affecting companies beyond Canada’s borders. The unveiling of the legal framework for legalized marijuana has alleviated concerns that the bill would have placed restrictions on export permits for existing medical marijuana producers, as such companies are moving to increase their efforts to export medical marijuana. Partner Eileen McMahon, an expert in IP and drug regulatory law, gave her perspective on the bill with Bloomberg in an excerpt from the article, below.
“You’re going to develop know-how on how to make this stuff,” said Eileen McMahon, a partner at Torys LLP and chair of the law firm’s intellectual property and food and drug regulatory practices. “That know-how arguably could be used” outside Canada under the Trudeau law, she said, adding it’s possible “employees with that expertise could cross the border.”
To read the full article, click here.